The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment.
 
In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability to slow cognitive and functional decline in individuals with early symptomatic Alzheimer's disease. This includes those with mild cognitive impairment or mild dementia. These findings support the initial topline data release made by Eli Lilly and Company in May 2023.
 
Participants who received donanemab experienced a significant slowing of decline compared to those who received a placebo. The beneficial effects of the treatment continued to increase throughout the trial, with the largest differences observed at 18 months.